An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed a JAK Inhibitor
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs KRT 232 (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Kartos Therapeutics
- 22 Nov 2019 Planned number of patients changed from 247 to 203.
- 06 Nov 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 21 Jul 2019 Planned number of patients changed to 247.